Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV)

3.75
Delayed Data
As of Aug 31
 +0.07 / +1.90%
Today’s Change
0.65
Today|||52-Week Range
5.76
+68.92%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$82.0M

Company Description

ContraVir Pharmaceuticals, Inc. is a development stage biopharmaceutical company which is focused primarily on the development of drugs to treat herpes zoster, or shingles. The company currently developing a compound called FV-100 for the treatment of shingles. It is also developing CMX157, a potent analog of the successful antiviral drug tenofovir DF (Viread). ContraVir Pharmaceuticals was founded on May 15, 2013 and is headquartered in Edison, NJ.

Contact Information

ContraVir Pharmaceuticals, Inc.
399 Thornall Street
Edison New Jersey 08837
P:(732) 902-4000
Investor Relations:
(212) 584-7610

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

James E. SapirsteinChief Executive Officer & Director
William HornungChief Financial Officer
John Z. Sullivan-BólyaiChief Medical Officer
Gem GokmenHead-Media Relations